iSpecimen Named Top Competitor in $4.4 Billion USD Market
iSpecimen (NASDAQ: ISPC) has been recognized as a top competitor in the Biospecimen contract research services market, currently valued at $4.4 billion USD and projected to reach $13.5 billion by 2032, growing at a 13.3% CAGR. The market growth is driven by expanding drugs and biologics demand, increased specialized testing needs, and requirements for novel clinical trial designs in cell and gene therapies.
The company has demonstrated expertise across market segments, sourcing over 90% of specimen categories, with particular strength in oncology research. Their marketplace offers researchers options to search by cancer type and access various oncological specimens. iSpecimen is actively expanding into cardiovascular and neurological disorder segments, positioning itself for continued growth in this expanding market.
iSpecimen (NASDAQ: ISPC) è stata riconosciuta come un'opponente di punta nel mercato dei servizi di ricerca contrattuale su biospecimen, attualmente valutato 4,4 miliardi di USD e previsto a raggiungere 13,5 miliardi entro il 2032, con una crescita del 13,3% CAGR. La crescita del mercato è guidata dall'espansione della domanda di farmaci e biologici, dall'aumento delle esigenze di test specializzati e dai requisiti per nuovi disegni di studi clinici nelle terapie cellulari e genetiche.
L'azienda ha dimostrato competenza in vari segmenti di mercato, approvvigionando oltre il 90% delle categorie di campioni, con particolare forza nella ricerca oncologica. Il loro marketplace offre agli studiosi la possibilità di cercare per tipo di cancro e accedere a vari campioni oncologici. iSpecimen sta attivamente ampliando la sua presenza nei segmenti delle malattie cardiovascolari e neurologiche, posizionandosi per una continua crescita in questo mercato in espansione.
iSpecimen (NASDAQ: ISPC) ha sido reconocida como un competidor destacado en el mercado de servicios de investigación contratada de biospecimenes, actualmente valorado en 4.4 mil millones de USD y proyectado para alcanzar 13.5 mil millones para 2032, con un crecimiento del 13.3% CAGR. El crecimiento del mercado se impulsa por la creciente demanda de fármacos y biológicos, el aumento de necesidades de pruebas especializadas y los requisitos para nuevos diseños de ensayos clínicos en terapias celulares y genéticas.
La empresa ha demostrado experiencia en varios segmentos de mercado, abasteciendo más del 90% de las categorías de especímenes, con una fortaleza particular en la investigación oncológica. Su mercado ofrece a los investigadores opciones para buscar por tipo de cáncer y acceder a varios especímenes oncológicos. iSpecimen está expandiendo activamente su presencia en los segmentos de enfermedades cardiovasculares y neurológicas, posicionándose para un crecimiento continuo en este mercado en expansión.
iSpecimen (NASDAQ: ISPC)는 현재 44억 달러로 평가되는 바이오스펙imen 계약 연구 서비스 시장에서 최고의 경쟁자로 인정받았으며, 2032년까지 135억 달러에 이를 것으로 예상되며, 연평균 13.3% 성장할 것으로 보입니다. 시장 성장의 원인은 확대되는 의약품과 생물학적 제제 수요, 증가하는 전문 테스트 필요성, 세포 및 유전자 치료의 새로운 임상 시험 설계 요구사항에 있습니다.
회사는 90% 이상의 샘플 카테고리를 소싱하여 다양한 시장 세그먼트에서 전문성을 입증했습니다. 특히 종양학 연구에서 두각을 나타내고 있습니다. 그들의 시장은 연구자들에게 암 유형별 검색 옵션을 제공하고 다양한 종양학 샘플에 접근할 수 있도록 합니다. iSpecimen은 심혈관 및 신경 장애 세그먼트로의 확장을 적극적으로 추진하여 이 확장 시장에서 지속적인 성장을 위한 입지를 다지고 있습니다.
iSpecimen (NASDAQ: ISPC) a été reconnu comme un concurrent de premier plan sur le marché des services de recherche contractuelle sur les biospecimens, actuellement évalué à 4,4 milliards USD et projeté pour atteindre 13,5 milliards d'ici 2032, avec une croissance de 13,3% en moyenne annuelle. La croissance du marché est portée par l'expansion de la demande de médicaments et de biologiques, l'augmentation des besoins en tests spécialisés et les exigences de nouveaux designs d'essais cliniques dans les thérapies cellulaires et géniques.
L'entreprise a démontré son expertise dans divers segments de marché, fournissant plus de 90% des catégories de spécimens, avec une force particulière dans la recherche oncologique. Leur marché offre aux chercheurs des options pour rechercher par type de cancer et accéder à divers spécimens oncologiques. iSpecimen s'étend activement dans les segments des maladies cardiovasculaires et neurologiques, se positionnant pour continuer à croître dans ce marché en expansion.
iSpecimen (NASDAQ: ISPC) wurde als führender Wettbewerber im Markt für vertragliche Forschungsdienstleistungen zu Biospecimens anerkannt, der derzeit mit 4,4 Milliarden USD bewertet wird und bis 2032 voraussichtlich 13,5 Milliarden USD erreichen wird, mit einer jährlichen Wachstumsrate von 13,3%. Das Marktwachstum wird durch die steigende Nachfrage nach Medikamenten und biologischen Produkten, den zunehmenden Bedarf an spezialisierten Tests und die Anforderungen an neuartige klinische Studiendesigns in der Zell- und Gentherapie getrieben.
Das Unternehmen hat Fachkenntnisse in verschiedenen Marktsegmenten nachgewiesen und bezieht über 90 % der Spezimen-Kategorien, wobei es insbesondere in der Onkologie-Forschung stark ist. Ihr Marktplatz bietet Forschern die Möglichkeit, nach Krebsarten zu suchen und auf verschiedene onkologische Proben zuzugreifen. iSpecimen erweitert aktiv seine Präsenz in den Segmenten für Herz-Kreislauf- und neurologische Erkrankungen und positioniert sich für ein kontinuierliches Wachstum in diesem expandierenden Markt.
- None.
- None.
Biospecimen Market To Exceed
Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a
Leslie Hoyt, the Company's Senior Vice President of Operations, commented, "For the second year in a row that we have been following InsightAce Analytic's groundbreaking market research, iSpecimen has made the list of key competitors in this rapidly growing industry. iSpecimen is pleased to be at the epicenter of this growth. We have developed and will continue to refine core strategies to capitalize on this marketplace."
The Company's core strategies include a focus on large segments within the Biospecimen market such as oncology. The Biospecimen contract research services market is segmented into the biospecimen types and therapeutics areas. Based on the type of biospecimen types, the market is segmented into oncological and non-oncological studies. The oncological studies are further segmented into formalin-fixed paraffin-embedded "FFPE" tissue, frozen tissue, plasma, serum and other biospecimens. The non-oncological studies are further segmented into blood products, human tissue and other biospecimens. The therapeutics area segment includes oncological disorders, neurological disorders, cardiovascular disorders and other therapeutic areas.
Ms. Hoyt continued, "Since our inception, we have sourced
About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contacts
Katie Field
kfield@ispecimen.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229255
FAQ
What is the projected market value for Biospecimen services by 2032?
What is the current market value and CAGR for the Biospecimen market where ISPC operates?
What are the main biospecimen categories offered by ISPC in oncological studies?
What percentage of specimen categories mentioned in the report does ISPC source?
What therapeutic areas does ISPC cover in its biospecimen services?
